@prefix bibo: <http://purl.org/ontology/bibo/> .
  @prefix owl: <http://www.w3.org/2002/07/owl#> .
  @prefix rdf: <http://www.w3.org/1999/02/22-rdf-syntax-ns#> .
  @prefix cc: <http://creativecommons.org/ns#> .
  @prefix ep: <http://eprints.org/ontology/> .
  @prefix xsd: <http://www.w3.org/2001/XMLSchema#> .
  @prefix dct: <http://purl.org/dc/terms/> .
  @prefix foaf: <http://xmlns.com/foaf/0.1/> .
  @prefix skos: <http://www.w3.org/2004/02/skos/core#> .
  @prefix void: <http://rdfs.org/ns/void#> .
  @prefix geo: <http://www.w3.org/2003/01/geo/wgs84_pos#> .
  @prefix eprel: <http://eprints.org/relation/> .
  @prefix rdfs: <http://www.w3.org/2000/01/rdf-schema#> .
  @prefix event: <http://purl.org/NET/c4dm/event.owl#> .
  @prefix doi: <https://doi.org/> .
  @prefix epid: <https://arxiv.universalpublishings.com/id/> .
  @prefix dc: <http://purl.org/dc/elements/1.1/> .

<>
	foaf:primaryTopic <https://arxiv.universalpublishings.com/id/eprint/63147>;
	rdfs:comment "The repository administrator has not yet configured an RDF license."^^xsd:string .

<https://arxiv.universalpublishings.com/id/eprint/63147#authors>
	rdf:_1 <https://arxiv.universalpublishings.com/id/person/ext-363f822b27d904573aa1c3043d94e745> .

<https://arxiv.universalpublishings.com/id/eprint/63147/>
	dc:format "text/html";
	dc:title "HTML Summary of #63147 \n\nSPECIFICITY OF TREATMENT OF PEPTIC ULCER DISEASE WITH H2 HISTAMINE BLOCKER DRUGS\n\n";
	foaf:primaryTopic <https://arxiv.universalpublishings.com/id/eprint/63147> .

<https://arxiv.universalpublishings.com/id/eprint/63147>
	bibo:abstract "Peptic ulcer disease (PUD) is a chronic condition characterized by mucosal erosion in the stomach or duodenum, resulting from an imbalance between aggressive gastric factors such as acid and pepsin, and defensive mechanisms including mucosal protection, prostaglandin secretion, and epithelial regeneration. Among the major therapeutic milestones in its treatment is the introduction of H₂ histamine receptor antagonists (H₂ blockers), which revolutionized gastroenterology by suppressing acid secretion effectively and promoting mucosal healing. This paper discusses the pharmacodynamics, pharmacokinetics, therapeutic specificity, and clinical implications of H₂ blockers such as cimetidine, ranitidine, famotidine, and nizatidine in the management of peptic ulcer disease. Emphasis is placed on their mechanism of action, comparative efficacy, drug interactions, side effects, and their role in the contemporary era of proton pump inhibitors (PPIs)."^^xsd:string;
	bibo:authorList <https://arxiv.universalpublishings.com/id/eprint/63147#authors>;
	bibo:status <http://purl.org/ontology/bibo/status/published>;
	dct:creator <https://arxiv.universalpublishings.com/id/person/ext-363f822b27d904573aa1c3043d94e745>;
	dct:date "2025-10-29";
	dct:isPartOf <https://arxiv.universalpublishings.com/id/repository>,
		<https://arxiv.universalpublishings.com/id/publication/ext-d62a5dbdabc792c15cf76756361a4d36>;
	dct:publisher <https://arxiv.universalpublishings.com/id/org/ext-20ef1f289b7920027328009b5eefe52c>;
	dct:title "SPECIFICITY OF TREATMENT OF PEPTIC ULCER DISEASE WITH H2 HISTAMINE BLOCKER DRUGS"^^xsd:string;
	rdf:type bibo:AcademicArticle,
		bibo:Article,
		ep:ArticleEPrint,
		ep:EPrint;
	rdfs:seeAlso <https://arxiv.universalpublishings.com/id/eprint/63147/> .

<https://arxiv.universalpublishings.com/id/org/ext-20ef1f289b7920027328009b5eefe52c>
	foaf:name "Center for Tech and Media Research"^^xsd:string;
	rdf:type foaf:Organization .

<https://arxiv.universalpublishings.com/id/person/ext-363f822b27d904573aa1c3043d94e745>
	foaf:familyName "Islombek"^^xsd:string;
	foaf:givenName "Sobirjonov"^^xsd:string;
	foaf:name "Sobirjonov Islombek"^^xsd:string;
	rdf:type foaf:Person .

<https://arxiv.universalpublishings.com/id/publication/ext-d62a5dbdabc792c15cf76756361a4d36>
	foaf:name "Multidisciplinary Journal of Science and Technology"^^xsd:string;
	rdf:type bibo:Collection .